Peptides selectively lethal to malignant and transformed mammalian cells
AssigneeThe Research Foundation of State University of New York
InventorMatthew R. Pincus
Life of this patent
Estimating the term…
Abstract
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein. When fused to a membrane-penetrating leader sequence, the peptides are either lethal to malignant or transformed cells or else cause reversion to the untransformed morphological phenotype. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide are also provided.
Claims13
A composition comprising a peptide, the peptide consisting of the amino acid sequence:
- PPLSQETFSDLWKLL (SEQ ID NO:1) fused to a membrane-penetrating leader sequence.
A composition comprising a peptide, the peptide consisting of the amino acid sequence:
- PPLSQETFS (SEQ ID NO:2) fused to a membrane penetrating leader sequence.
A composition comprising a peptide, the peptide consisting of the amino acid sequence:
- ETFSDLWKLL (SEQ ED NO:3) fused to a membrane penetrating leader sequence.
A composition comprising at least one peptide consisting of the amino acid sequence:
- PPLSQETFSDLWKLL (SEQ ID NO:1), PPLSQETFS (SEQ ID NO:2), or ETFSDLWKLL (SEQ ID NO:3), said peptide fused to a membrane penetrating leader sequence.
A method of treating neoplastic disease in a subject, said method comprising administering to the subject, a therapeutically effective amount of a composition comprising at least one peptide consisting of the amino acid sequence:
- PPLSQETFSDLWKLL (SEQ ID NO:1), PPLSQETFS (SEQ ID NO:2), or ETFSDLWKLL (SEQ ID NO:3), said peptide fused to a membrane penetrating leader sequence.
Dependencies are inferred from the claim text.